REGISTERED COMPANY NUMBER: 05017662 IEn8land and Wales) REGISTERED CHARrrY NUMBEA: 1106320 Re olthe Trustees and Unau Flnanclal Ststements for the Year Endèd 31 December 2023 for THE BRITISH ASSOCIAnON FOR THE STUDY OF THE LIVER A COMPANY LIMITED BY GuARATrEE Elsby & Co Isywelll Ltd Chartered Ac¢ountsnts 155 Welllngborough Road Rushden Northamptonshife NNIO 9TB
SH oci THE LIV Conten for the h FlnancFal Statemen r ende I DECEMBER 20 Pale Report of the Trustees I to 5 Independent Examlner's Report Statement of Flnandal Adl¥ltl@s Balance Sheet Cash Flow Ststement io Notes to the Cash Flow Ststement li Notes to the Flnanclal Statements 12 to 18 Detalled Statement of Flnandal ArtlvltSes 19
E8RI CIATION FO THE UV THE DY ort of the Tru ear ended 310E es rthe EMBER 202 The trustees who are also dlrectors of the charity for the purposes of the Companies Act 2006, present thelr report with the financlal statements of the charity for the year ended 31 December 2023. The trustees have adopted the provisions of Accounting and Reporting by Charitie5.' Statement of Recommended Practice applicable to charlties preparlng their account5 In accordance with the Financial Reportlng Standard applicable in the UK and Republic of Irèland IFRS 1021 (effectivè l January 20191. The financial statements have been prepared in accordance with the accounting policSes set out in notes to the accounts and comply with the charity's 8overning document, the Charities Act 2011 and Accounting and Reportlng by Charities.. Statement of Recommended Practice applicable to charities preparing their accounts in accordance wlth the Flnanclal Reporting Standard applicable in the UK and Republic of Ireland published on 16 July 2014 la5 amended by Update Bulletin I published on 2 February 20161. oBJEIVEs AND AcnvmES Oblectlve$ and alms The objectives of the company, as Set out in the Memorandum of AssocSatSon as amended by Special Resolution. are to advance education and awareness in liver disease and disorder, by the provision or the facilitation of research directed towards the development and evaluation of treatment of such disease and disorders. The trustees confirm that they have referred to the guSdan¢e contained in the Charity Cornmi55ion's guidance on public benefit when reviewing the associatiori'5 aims and objectives and In plannlng future activitie5. The Trustees carry out these objecls by.. Having educational meetings for medical professionals to attend to further theii knowledge and advance education. awareness and research into liver disease. Supportin8 special interest groups to further education of specific areas of liver disease. To asses5 success in the reporting period, BASL aim to maintain and increase membership, provide educational events- predominantly the Annual Scientific Meeting. To maintain Sufficient funds to allow these activities to take place. Contrlbutlon The £ontributlon of eath Inember 55 lin)Ited to £1 In tl)e eveiii uf4 disxjlution of the Company. Page I
THE BRMSH ASSO IATION F THE LIVER R ThE ¥niDYOF Re ort of the Trvstees ear ended I DECEMBER 20 for the sfRATEGIC REPORT Achlevement and performan Charmable actlvltlès BASL Annual Meetlng Ilncorporatlng the annual BTLG and BLNA meetln81 The 2023 BASL Annual meetin8 was held at the DoubleTree Metropole in Brlghton and proved to be a great success providin8 Int•raction and learning opportunStlC&. Thcrc wcrc 639 dcle88tes across all three rneet1n whlch made an ex¢ellent surplus. The Sheila Sherlock priie went to Dr Kushala Abeysekera and Dr Oliver Tavable received the Andrew 8urrou8hs Young Investigator award. BASL Schools ÈASL Schools are small 8roup meètln8s provlded free of charge to tralnee members In Gastroenterolo8y and Hepatology that deliver structured education and interactlon with experts in the field. These help the ¢harity to meet Its objertives by committing to improving clinical education and training for tomorrow's Hepatology Consultants, Trainees inteTested in transplantatTon and anaesthesia. These were held as 6 Interactive Weblnars. These proved to be a great success and feedback wa5 excellent. BASL Xtra Thi5 is an online educational conference and was the second one io be held. This a multi-profe5sional, topic focused educatlonal online event. Attendance and surplus were excellent and the decision wa5 made to continue to hold thls event annually. BASL Introductlon to Hepatolo8y Day The meeting was held in Birmingham. This wa5 deemed to be a great 5ucce5s and provided a small surplus. BVHG Meetln85' Two meetlngs were held in 2023 due to the 2022 meetlng being delayed unt51 January 2023. These meetlngs were very popular and provlded an excellent surplus. BASL 8asSc Sclence Retreat Thls was held in London and any shortfall was covered by the Institute of Hepatology. who organised the event on behalf of BASL. Thls was very popular and well attended. 5pectal Irrterest Groups BASL provides ongoing admlnlstratlve support to a number of established Special Interest Groups ISIGS) whose remit Is to promote and encourage ¢ollaborative research and clinleal tfials in liver disease. HCC-UK Annual Meetlng This was held at the Royal College of Physlclans In Edinburgh. This wa5 very well attended and mède an excellent. surplus CCA-UK Annual Meetlng This was held in Nottingham and made a significant deficlt. Changes were made to future format for this meeting to prevent more deficit. BAAL This was ihe first meeting tor thls newly formed 8foupi held In Birmingham. Costs were covered and a small surplus was made. BHPG Educatlonal Meetlng Meetings were held in Febmary and November In 2023 and a good surplus was made due to good sponsorship belng achieved. Secretsrlat Secretariat servir.es were provlded by Executive Bvslrtess Support Ltd. Page 2
Rm OCIAfoN THE LIVER R THEsfuDY ort of th Trustees nded 310ECEMBEK2023 for th ear TO ensure a balanced picture of the charity's progress against its objectives, sufficient funds are rnalntained to allow the Desired educational events held to continue to take place. The key performance Inditators to explaln outputs achleved by activities are the level and number5 of members Ini1¥651n& as well as rnalnialnlng (Jelegate member5 at edu¢ationai events. Flnanclal revlew Flnandal posltlon Detailed finance reports are produced for the Tiuslee5 for every gove¥nln8 board meeElng. The Trusiees aim io achSeve a Surplus or Breakeven for every Èducatlonal meeting. The results for the year are shown on page 16. The trustees alm to hold sufficient reserves to support key rneetings in the event of potential shortfalls in income. The membership and subscriptions database has been updated and clarified and the charity currently ha5 1,624 12022.. 1,4231 active members. The BASL website continued to provide a good platform for providing news and information as well as serving as an interactive communications and education hub for rnembers. The ¢harity managed to athieve incorne of £533,53912022'. E397,8921 during the year. Cash reserves have been stable at £261,21012022'. £206,737) due to the charlty continuing to hold events on a virtual basis, as well a5 face to face. resulting in lower costs as a result and in addition, increasin8 membership fees. The trusteès believe that the charlty has suffieient reserves to continue and hopes to achieve a greater surplus in 2024 with the aim of holding events on a face to face basi5. as well as some on a virtual basis. The charity always hopes to retain reserves in unrestricted funds to cover 24 months operational costs and at the end of the accountin8 period, these had decreased to £173.61512022.. £125.0011. It is hoped that reserves will return to forrner levels over the ne¥t ¥0 years and be able to cover 24 months of operatinnal rngts during the 2024 and 2025 atcountin8 periods. Significant events that have affected financial performance and financial position during the pèritsd, include an Increase in fa¢e to face meetings held, followin8 more virtual event5 durin8 2020 2022 due to Covid. This resulted in an increase In ¢osts to hold meetings as well as increased sponsorship and delÈeatp. inc.nmp fiose atténtion is made to ensure all events held make a surplus or at the very least cost neutral. Factor5 likely to affect future financial performance or position are the advancement in medical science resulting in an intrease in education of the members and potential increase In sponsorship from Pharmaceutical companies to promote new treatments. Principal funding sources are the membership income as well as sponsorship from Pharmaceutical ¢omDanies and delÉ*gxte incom from events. ReseNes poll¢y Reserves are needed as sponsorship by PharmaceutScal companies of educational events. which are one of the kp.y objectives Of BASL, can drop suddenly depending on the current fo¢u5 of the Pharmaceutical Companie5. As stated in the Articles of Association.. The Association will airn to retain sufficient capital funds in Teserve to permit it to conduct its activities as defined by the Governing Board for a period of years in the absence of any incorne over this peflod. Future Developments The Trustees airn to continue to provide educational meetings and other member benefits In accordance with the objectives of the Charity. The experience of the pandemlc has resulted in the ability to run meetings on a virtual basls to ensure events still takè place. making meetSngs accessible to members and meanlng external risk factors are more manageable. srRucfuRE, GOVERNANCE ANO MANAGEMENT Govemlng document The charity is controlled by Its 8overnln8 document, a deed of trust, and constitutes a Ilmited company, limited bv guarantee. as defined by the Companies Act 2006. Page 3
E BR ASSOCIAn THE LIVER RTHE Re ort of the Tr ear ended 31 DECEMBER 20 ee for the STrUCWRE. GOVERNANCE AND MANAGEMENT Induttlon and tralnln8 of new trustee5 Newly elerted trvstees attend quarterly meetings wlth the Chairperson and the governlng board to observe the provlslon of services to member5. They are also 8lven 8uidance which include an outllne of thelr role and a handover from the out8olng Trustee. The charfty makes decisions through it's governing board. Pollcles and pro¢edures for Induction and tralning of trustees Is supported by the current and outgoing Trustees. REFERENCE AND ADMINisfRATIVE DAlL5 Re8lstered Company number 05017662 (England and Wale51 Re815tered Charlty number 1106320 ReBlstered offi Executive Business Support DadSOn Road Ll¢hfield Staffordshire WS14 9DZ Trustees Dr TJ S Cross Consultant Hepatologist lappolnted 22.9.231 Professor B R Davidson Hepatobiliary and Transplant Consultant Iresigned 22.9.231 Dr TJ Kendall Senior Clinical Fellow In Pathology Dr l A C Rowe University Clinical Academic Fellow Dr V_qnnwdon Consijltant HÈpatolo8i5t M5 M B Clayton Lecturer In Liver Care Dr M A Afdersley Consultant Hepatologi5t Ires18ned 1.2.231 Dr K J Simpson Consultant Physician and Senior Le¢tiJrer (resigned l.10.231 Profe5$0r M E Cramp Consultant Hepatologist Dr A M Elsharkawy Consultant Hepatolosist Dr R Jones Consultant Hepatologist (resigned 22.9.231 Dr K Drysale Hepatolgy Registrar Clinical Research IrÈsigned 31.1.231 Professor R Mookerjee Professor of Translational Hepatology Dr M Allison Consultant Hepatolo8lSt Dr S Chokshi Acting Director & Chief Scientific Offic Dr O A A Elshaarawy lappointed 18.5.231 Professor P Kennedy Consultant Hepatologtst and Gastroentero (appointed 30.1.231 Mrj A Flichard Doctor (appointed 31.10.231 Independent Examlner Carl Elsby AfA Elsby & Co Isywelll Ltd Chartered Accountants 155 W¥llin¥bort)u¥h Rodd Rushden Northamptonshire NNIO 9TB Pase 4
CIATION FOR TH THE UVER he Trustees ar ended 310ECEMBER 2 for Report of the trustees. Incorporating a strateglc report. approved by order of the board of irustees, as the tompany dlrertors, on ....... J.J..:..k2kg.......... and signed on the board's behalf bv.. Dr M Elsharkawy- Trustee Page 5
Inde end Examlner's R The Brltlsh Assoclatlon for the S the Llve ees of Independent examlner's report to the trustees of The 8rltlsh Assoclatlon for the Study of the Uver I'the Companv'l I report to ihe charity trustees on my examination of ihe accounts of the Company for the year ended 31 December 2023. RÈsponslbllltl•s and bas1$ of report s the charlty'5 trustee5 of the Company land also Its dlrectors for the purposes of company lawl you are responsible for ihe preparation of the accounts in accordance with the requlrernents of the Cornpanles Act 20061'the 2006 Act'l. Hawng 5at15fied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are ellble for independent examination, I report In respect of my examination of your charity's accounts as ¢arried out undef Section 145 of the Charitles Act 2011 I'the 2011 Aet'l. In carrying out my exarnlr¥aiion I have followed the Direction5 8iven by the Charlty Cornmission under Sectlon 145151 Ibl of the 2011 Act. Independent examlner's statement Since your charity's gross income exceeded £250,000 your examlnei must be a member of a listed body. I can confirm that l am qualified to undertake the examinatSon because l am a member of the Institute of Chartered Accountants In England and Wales. which is one of the Ilsted bodies. I have completed my examlnatlon. I confirm that no matters have come to my attention Sn connectlon with the examination 8ivlng me cause to believe.. accovntlng re¢ord5 were not kept In resped of the Company as requlred by Section 386 of the 2006 Act,. or the accounts do not accord wlth those re¢ord5,' or the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any Tequirement that the accounts glve a true and fair view whlch is not a matter considered as part of an independent examlnatlon; or thè accounts have not been prepared in accordance wlth the methods and principles of the Statement of Recommended Practice for accounttng and reportlng by charities (applicable to charitles preparing their accounts In accordance with the Financlal Reporting Standard applicable in the UK and Republic of Ireland IFRS 10211. I have no concerns and have come across no other matters in connertion with ihe examination to which attention should be drawn in thi5 report In order to enable a proper under5tandlng of rhe accounts to be reached. Carl Elsby ACA Elsby & Co Isywelll Ltd Chartered Accountants 155 Welllngborough Road Rushden Northampton5hire NNIO 9TB Date.. I st October 2024 Page 6
E8R IATION F THE UVER atem nt of Flnan ttlvltl ear ended 31 DECÈMBER 202 for 2023 Total funds 2022 Total funds Unrestrlcted funds Restrltted funds Notes INCOME AND ENDOWMENTS FROM Mèmbership subscriptlons 116,383 116,383 99.160 conferen fees & sponsorshlp Income Interest recelvablè 413,049 4,107 413.049 4.107 297,904 1 828 397.892 Total 533,539 533,539 EXPENDtruRE ON Conference costs Dirett conference costs Other associated conference costs 287,534 189,113 287,534 189.113 206,048 197,398 476,647 476.647 403.446 Other 9.014 9.014 13,476 416.922 Totsl 485.661 485.661 NEf INCOMEIIEXPENDfwREI 47,878 47.878 119,0301 RECONCIUATION OF FUNDS Total funds brought forward 125,001 22,377 147,378 166.408 ', TOTAL FUNDS CARRIED FORWARD 172.879 22,377 195.256 147,378 CONTINUING OPEKATIONS All income and expenditure has arlsen from contirtulng activities. The notes form part of these financlal statements Page 7
THE BRMSH A550CIATION FOR THE STUDY OF THE LIVER Balance Shee 31 DECEMBER 2023 2023 Total fund5 2022 Total funds Unrestricted funds Restricted fund5 Note5 FIXED A55Efs Investments 12 CURRENT ASSETS Debtors.. amount5 fallin8 due wlthln one year Cash at bank 13 40,753 238,833 40,753 261,210 17,893 206,737 22.377 279,586 22,377 301.963 224,630 CREOITORS Amounts falling due wSthln one year 14 169,9261 169.9261 145,1291 NET CURRENT ASSETS 209,660 22,377 232.037 179.501 TOTALASSEfs LESS CURRENT UABiunES 209,661 22.377 232,038 179,502 CREDITORS Amounts fallirb8 due after more than one year 15 136,7821 136.7821 132,1241 NEfASSErs 172,879 22,377 195,256 147,378 FUNDS Unrestrled fitnds.. General fund Restricied funds.. BASL nurses fund CCA UK Nell Blenkinsop donatlon for research only 16 172,879 125,001 6,627 15,750 6.627 15,750 22,377 22,377 TOTAL FUN05 195,256 147.378 The charltable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023. The mernbers have not required the Company to obtaln an audit of Sts finantial staternents for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006. The note5 form part of these financlal statements Pagè 8 contlfiued..
BRMSH NFOR THE UV Balance sheet. contl 31 DECEMBÉR The trustees aeknowled8e thelr responslbilities for ensurSng that the charitable company keeps a¢¢ountSng records that comply wilh Sectlons 386 and 387 of the Companies Act 2006 and preparinR ftnancial statements whlch give a true and fair vlew of the state of affalrs of the charltable company as at the end of each financial year and of its surplus or defi¢lt for each financial year in ac¢ordance with the requlrements of Sections 394 and 395 and whlch otheTwSse comply with the requirements of the Companies Ad 2CKJ6 relating to financial statements, so far as appllcable to the charStable company. Ibl hnanclal staternents were approved by the Board ol Trustees and aurhorlsed for 155ue and were signed on Its behalf by.. on sharkawy- Trusiee The notes form part of these finan¢lal stst4m•nts Page 9
ThEBR H ASSOCI N FOR THE miDY OF THE LIVE Ca h Flow Sta ar end 31 DECEMO ern for the R 2023 2023 2022 Notes Cash flow5 from opÈratln8 actlvltles Cash 8enerated from operations 50.366 15,4491 Net cash provlded byllused Inl operating activltles 50,366 15,4491 sh flows from Investln8 actlvltles Interest received 4,107 828 Net cash provlded by Snvesting activitles 4,107 828 Change In cash and cash equl¥alents In the reportln8 perlod Cash and cash equlvalents at the be8lnnlrbB of thè reportln8 perlod 54.473 14,6211 206,737 211,358 Cash and cash ÈqulvèlÈnts at the end of the reportln8 perlod 261,210 206,737 The notes form part of these flnanclal statements Pa8e 10
E BRMSH IATION FOR TH THE UVER DY e5 to the Cash Flow Stateme for the ear ended 31 DECEMBER 2 RECONCIUATION OF NET INCOME/IEXPENDmJAEI TO NET CASH FLOW FROM OPERATING AcnvtriES 2023 2022 Net Incomellexpendlturel for the reportlng perlod las per ihe Statement of Flnanclal Acllvltles) AdJu5tmertts for: Interest received Increase in debtors Increase in creditors 47,878 119,0301 14,1071 122,8601 29,455 18281 13.4291 17,838 Net cash prnvlded byllused Inl operatlons 50,366 15.4491 ANALYSIS OF CHANGES IN NET FUNDS At 1.1.23 Cash flow At 31.12.23 Net cash Cash at bank 206,737 54.473 261.210 . 206,737 54.473 261.210 Total 206,737 54.473 261,210 The notes form part of these financial statements Page 11
THE 8RITIS CIATI THE LIVER RTH OF Not for the s to the flnandal 5t tem ar ended 31 DECEMBER 20 ACCOUPlllNG POUCIE5 General Inforniatlon The charity Is a private company Ilmlted by guarantee, registered in England and Wale5 and a reglstered charity In England and Wales. The address of the re8lStered office Is Executlve Business Support, Davidson Road, Llchfleld. Staffordshire, En8land, WS14 9DZ. Ba515 of preparlng the financlal statement5 The fin8nei81 statements of the charltable companyi whleh Is a publlc beneflt entity under FRS 102. h3V@ b@en prepared in accordance with the Charliles SORP IFRS 1021 'Accountln8 and Reportlng by Charities.. Statement of Recommended Practice appll¢able to eharltles preparlng thelr accounts in accordan¢e with the Flnancial Reportin8 Standard applicable in the UK and Republic of Ireland IFRS 1021 (effective l January 20191,, Flnanclal Reporting Standard 102 'The Financlal Reportlng Standard appllcable In the UK and Republic of Ireland, and the Companies Act 2006. The finaneial statements have been prepared under the historlcal cost convention, with the exception of investments whlch are Inclyded at market value. The presentational currency of BASL Is consldered to be pounds sterlin8 and the financial statements are rounded to the nearest pound. Incomln8 resou@S All income is recognised In the Statement of Flnanclal Activities once the charlty has entitlement to the funds, It IS Probable that the Income wlll be recelvéd and the amount can be measured reliablv. Income recelved for a specific restrlcted purpose Is credited to a separate restrlcted fund whlch Is shown in a note lo the financlal statements. Total Incomlng resources credited to restrlcted funds are di5¢10sed on the statement of financial activities whlch a150 show5 incorninB resources in respect of unre5tTlCted funds. Conferente income represents fees and sponsorshlp received in re5pert of conference'5 or8anised in pursult of the company's charitable objective5. Income assoclated wSth conferences of future accounting perlods Is treated as deferred income. Resources expended Liabilities are recognised as expendlture as soon as there 15 a legal or constructlve obligation committing the charity to that expenditure. it 15 probable that a transfer of economi¢ benefits will be required in settlement and the amount of the obligation can be measured reliably. Where costs cannot be directly attributed to partiriJl?r hpadin8E thpy hxvp heen allocated to artlvities on a basis consistent with the use of resources. Resources expended are included In the statement of financial activltles on an accrual basis exclvsive of VAT. I Irrecovefable VAT is charged against the category of resource5 expended for which it was incurred. Taxatlon The activities of the charity are exempt from Corporation Tax under Section 505 of the Income and Corporatlon Trxe5 Aa 1988 IQ the extent that ihey are applled to the organisaiion'5 charitable objects. Fund accountlng Unrestricted funds are donation5 and other incoming resources received or generated for the general charltable purposes of the charity. Within unrestricted funds are deslRnated Tunds. The nature of each of the de5iBnated fund% is referred to within the report of the trustees. Restricted funds can only be used for paitlcular restricted purposes within the objects of the ¢harlty. Restrirtions arise when specified by the donor or when funds are ralsed for particular restricted purpose5. Page 12 contlnued...
THE MSHAS IATION FOR THE THE LIVER Notes to the Flnan atements- contlnu for the ear ended 31 DECEMBER 2023 ACCOUNTING POLICIES- contlnued Debtors and creditors Short term debtors are measured at transaction price (which is usually the invoice pricel, less any Impairrnent lossès for bad and doubrful debts. Loans and other financial assets are initialSy recognised at transaction price Including any tran5a¢tion costs and subsequently measured at amortised cost determined usin8 the effective interest method, legs any impairment losses for bad 3nd doubtful debts. Short term creditors are measured at transactlon prlce Iwhlch Is usually the invoice pricel. Loans and other financial liabilities are initially recoBnised at transaction price net of any transaction costs and subsequently measured at arnortised cost dete¥mlned usln8 the effective interest method. Cash and cash equlvalents Cash and cash equivalents include cash In hand and deposits held at call with banks. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY In preparin8 the financial statements It is rtecessary to make ¢ertain judgements, estirnates and assumptions that affect the amounts retognised int he financial staternents. In the view of the trustees in applyin8 the accounting policies adopted, no judgements were required that have Sl8nificant @ffect on the amounts re¢o8nised in the fin3n¢ial statements nor do any estimatès or assumptions made carry a significant risk of material adjustment in the next financial year. MEMBERSHIP SUBSCRIPTIONS 2023 2022 Grants Subs¢ription5 12,729 103,654 99.160 116,383 99.160 Grants receivable are credited to the Statement of Fin3ncial Activtiies ISOFAI in the year for the year for which they are received. Deferred income represents amounts received for future periods an dis Teleased to incomlng resources in the period for which it has been received. CONFERENCE FEES & SPONSORSHIP INCOME 2023 2022 Conference income 413,049 297,904 Page 13 continued,-.
BR CIATION FOR THE STUDY THE UVER Note5 h Mnanclal atements. contlnued for the nded 31 DEC MBER 2 INTEREST RECEIVABLE 2023 2022 InteTe5t receivable 4,107 828 DIREcf CONFERENCE COSTS 2023 2022 Annual conference costs Annual 5UPPOrt to UKLA 274,284 13,250 194.548 ii.soo 287,534 206,048 MER ASSOCIATED CONFERENCE Cosrs 2023 2022 Travel & hotels ArtworVdesi8n & prlnt CPD application Bank charges Website Secretarial support costs EBS Costs Partial exemptlon input VAT 12,511 4.216 956 5,282 4,408 8.044 170,635 116,9391 2,242 3.536 4,196 6,185 5,751 175,204 189.113 197,398 SUPPORT COSTS Governance costs Other resources expended 9.014 INCOMEIIEXPENDtruRE) Net incomellexpendlturel is stated after charginyJlcTeditingl'. 2023 2022 AOUntanCY fees 5,012 5.047 Page 14 continued...
ThEBR SH OCIATION FOR THE STUDY OF THE UVER t@s tD tho Fln3nclal for the ar -to ded 31 DECE BER 20Z3 io. TRUSTEES, REMUNERATION AND BENEFITS No trustees recelved any remuneiation durlng the current or prior year. Trustees, expenses Travel and speaker expenses totalling E525.3612022.. £728.30) were relmbursed to 412022. 41 trustees during the year. ii. COMPAPATIVES FOR THE STATEMENT OF FINANCIAL AcnviTIES Unrestricted funds Restricted funds Total funds INCOME AND ENDOWMENTS FROM MembershÉp subs¢riDtions 99.160 99.160 Conferènce fees & Sponsorship income Interest receivable 297,904 828 297,904 828 Total 397,892 397,892 EXPENDITURE ON Conference tosts Direct Conference costs Other assoclated conference costs 206.048 197,398 206,048 197,398 403.446 403.446 Other 13,476 13,476 Total 416,922 416.922 NET INCOME/IEXPENDITUREI 119.0301 119,0301 RECONCIUATION OF FUNDS Total funds brought forward 144.031 22,377 166,408 TOTAL FUNDS CARRIED FORWARD 125,001 22.377 147.378 Page 15 continued...
BRMS IATI THE LIVER THE DYOF es to th Flnanclal Stateme - contlnu for the ar ended 31 DECEMBER 202 FIXED ASSEf INVESfMETrS Unllsted Investments mARKVALuE At l January 2023 and 31 December 2023 NEf BOOK VALUF At 31 December 2023 At 31 December 2022 There were no Investment assets outside the UK. DEBTORS: AMOUNTS FALLING DUE WIThIN ONE YEAR 2023 2022 Trade debtors Prepayments 32,418 8,335 17,51XI 393 40,753 17,893 14. cREDoRS. AMOUNTS FALLING DUE WITHIN ONE YEAR Dthrred Income 2023 2022 Deferred Income at l January 2022 Resource5 deferred during the year Amounts released from prior year 23,000 23,780 I23,OclI 14.000 23,000 114,(MXJI Deferre(I Income at 31 December 2022 23,780 23.CQO Deferred income relates to income received In the year speclffically relatlft8 to performance conditions to be met in the following year. Page 16 continued...
THE BRITISH SOCIATION FOR THE STUDY THE LIVER Note to the Fln nclal Statements- contlnued for the ar ended 31 DECEMBER 2 15. CREDMRS: AMOUNTS FALUNG DUE AFTER MORE THAN ONE YEAR 2023 2022 Bursary Fund- support for members to attend meetlngs Swansea health economics work to accompany HCCUK Projec BLNA restricted fund 24.303 20.381 17361 12,479 12.479 36,782 32,124 16. MOVEMENTIN FUNDS Net movement in funds At 31.12.23 At 1.1.23 Unrestrlttèd funds General fund 125,001 47,878 172,879 Restrlcted funds BASL nurses fund CCA UK Neil Blenkinsop donation for Tesear¢h only 6.627 6,627 15.750 15.750 22.377 22,377 TOTAL FUNDS 147,378 47,878 195,256 Net movement in funds, included in the above are as follows: Incoming resources Resources expended Movement in funds Unrestrirted funds Genefal fvnd 533,539 1485,6611 47,878 TOTAL FUNDS 533.539 1485,6611 47.878 page 17 ontlnued...
THE BRMSH CIAn FOR THE LIVER UDY OF Note t the Flnanclal S for the ear ended ents- contlnu I DECEMBER 202 16. MOVEMENT IN FUNDS- contlnued CDmparatlve5 for movement In funds Net movement In funds At 31.12.22 At 1.1.22 Unrestrl¢ted funds General fund 144,031 119,0301 125.001 RÈstrlrted fvnds BASL nurse5 fund CCA UK Neil Blenklnsop donation for research onlv 6,627 6,627 15,750 15,750 22,377 22,377 TOTAL FUNDS 166.408 119,0301 147,378 Comparatlve net movemènt in funds. Included In the above are as follows: Incomrft8 resources Resources expended Movernent In fund5 Unre5trfrted funds General fufid 397,892 1416,9221 119,0301 TOTAL FUNDS 397.892 1416.9221 119,0301 17. RELATED PARTY DISCLOSURES There were no related party transaction5 for the year ended 31 December 2023. Pa8e 18
BRrrisH OCIA THE LIVER. THE DY alled or the atement f F al A Ivlties ear en ed 31 DECEMBER 2023 2023 2022 INCOME AND ENOOWMENTS Membershlp subscrlptlons Grants Subscriptions 12,729 103,654 99.160 116,383 99,160 Conference fees & sponsorshlp Income Conference income 413.049 297,904 Interest recelvable Interest receivable 4,107 828 Total Incomlng resources 533,539 397,892 EXPENDITURE D]rect conference costs Annual conference costs Annual support to UKLA 274.284 13,250 194.548 ii.soo 287,534 206.048 Othèr assoclated tonference tosls Travel & hotels Ath40rk/de5i8n & prlnt CPD application Bank charges Website Secretarlal support costs E85 Costs Partial exemption input VAT 12,511 4.216 956 5,282 4,408 2,242 3,536 4,196 6,185 5,751 175,204 170,635 116,9391 189,113 197,398 Support Costs Governance costs Accountancy fees Other legal and professlonal 5,012 4.002 5,047 8,429 9,014 13,476 Total resources expended 485,661 416.922 Net Incomel{expendlture) 47,878 119,0301 Thls page does not torm part ot the statutory financlal stafements Page 19